Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthRX vs Primary Clinic (Direct GLP)

HealthRX
Graded #8

Higher grade

vs+17.39999999999999
Primary Clinic (Direct GLP)
Graded #144

Lower grade

The verdict

HealthRX takes it — 86.1/100 to 68.7/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +7
85
78
Dose & formulationHealthRX +36
90
54
Clinical oversightHealthRX +12
87
75
Labs & monitoringHealthRX +6
82
76
FulfillmentHealthRX +13
86
73
Contract termsHealthRX +44
85
41
HealthRX · left barPrimary Clinic (Direct GLP) · right bar

The numbers

MetricHealthRXPrimary Clinic (Direct GLP)
WeighScore86.1/10068.7/100
GradeBC
Scorecard rank#8#144
Semaglutide$189/mo$65/mo (0.25 mg dose, promotional rate, compounded)
Tirzepatide$349/mo$110/mo (2.5 mg dose, promotional rate, compounded)
CoverageNot publicly listed10 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
  • Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
  • 503A pharmacy partners not named
  • LegitScript certification not mentioned on the site
  • Medical director and corporate legal entity not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard